CN105833132A - Drug for treating morbid leukorrhea - Google Patents

Drug for treating morbid leukorrhea Download PDF

Info

Publication number
CN105833132A
CN105833132A CN201610287707.4A CN201610287707A CN105833132A CN 105833132 A CN105833132 A CN 105833132A CN 201610287707 A CN201610287707 A CN 201610287707A CN 105833132 A CN105833132 A CN 105833132A
Authority
CN
China
Prior art keywords
parts
herba
leukorrhea
toxicity
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610287707.4A
Other languages
Chinese (zh)
Inventor
包莉丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610287707.4A priority Critical patent/CN105833132A/en
Publication of CN105833132A publication Critical patent/CN105833132A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/483—Gleditsia (locust)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/486—Millettia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A61K36/8984—Dendrobium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Insects & Arthropods (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a drug for treating morbid leukorrhea .The drug for treating the morbid leukorrhea is prepared from, by weight, 10 parts of stems and leaves of argyreia obtusifolia Lour., 9 parts of Japanese pachysandra herb, 15 parts of herba hyperici sampsonii, 9 parts of chicken bones, 9 parts of girald pleurospermum herb, 6 parts of seeds of chlorophytum comosum (Thunb.) Baker., 30 parts of sargentg loryvine stems, 20 parts of herba patriniae, 20 parts of glabrous greenbrier rhizomes, 10 parts of Chinese honeylocust spines, 15 parts of myrrh and 10 parts of kudzuvine roots .According to the drug for treating the morbid leukorrhea, stems and leaves of argyreia obtusifolia Lour .are bitter in taste and cool in property, dissipate blood stasis and stop bleeding; Japanese pachysandra herb clears heat, removes toxicity, regulates menstruation, activates the blood and stops leukorrhea; herba hyperici sampsonii clears the heat, removes the toxicity, promotes menstruation, activates collaterals, cools the blood and stops bleeding; chicken bones remove the toxicity, diminish inflammation, dispel wind and eliminate dampness; girald pleurospermum herb warms the middle warmer, regulates qi, tonifies the spleen, eliminates dampness and stops leukorrhea; seeds of chlorophytum comosum (Thunb.) Baker .moisten the lung for arresting a cough, dissipate the blood stasis and regulate the menstruation; sargentg loryvine stems have the effects of clearing the heat, removing the toxicity, eliminating carbuncle and resolving lumps, and the leukorrhea is weakened by means of pausing, so that sargentg loryvine stems serve as the main drug; herba patriniae, glabrous greenbrier rhizomes and myrrh clear the heat, remove the toxicity, promote diuresis, eliminate the carbuncle and expel pus; Chinese honeylocust spines achieve pus draining and toxin expelling and carbuncle eliminating; kudzuvine roots are pungent-cool and benefit for the spleen and stomach, and qi ascending is achieved by means of the effects of kudzuvine roots for ascending yang and invigorating clear yang of the spleen and stomach; all the drugs are combined for use and together achieve the effects of clearing the heat, remove the toxicity and promoting diuresis .The drug can safely and effectively treat the morbid leukorrhea.

Description

A kind of medicine under treatment belt
Technical field
The present invention relates to a kind of Chinese medicine, be specifically related to a kind of medicine under treatment belt.
Background technology
The traditional Chinese medical science " leukorrhagia " generic modern medicine " acute cervicitis " category, is with many stench, the color and luster exceptions of vaginal secretions amount, and is main clinical manifestation with General Symptoms.
Acute cervicitis is owing to many reasons causes the actute infection of cervix uteri.Primary disease often occurs with acute vaginitis or acute endometritis simultaneously.Cardinal symptom is that cervix uteri is red and swollen, and has a large amount of purulent secretion, and whole body may have grade fever.Acute cervicitis is the most rare, is mainly seen in septic abortion, obstetric infection, cervical lesions and vaginal foreign body accompanying infection, and pathogen is staphylococcus, streptococcus, enterococcus etc..Recently as the increase of sexually transmitted disease (STD), acute cervicitis is more typically.The clinical modal acute cervicitis of I is mucopurulent cervicitis (MPC) at present, and feature is that naked eyes see purulence or mucus purulent secretion on cervical canal or cervical canal cotton swab specimen, during with cotton swab wipe cervical canal, easily induces local hemorrhage.The pathogen of MPC is mainly Diplococcus gonorrhoeae and chlamydia trachomatis, and the pathogen of part MPC is failed to understand.Chlamydia trachomatis and Diplococcus gonorrhoeae all infect cervical canal columnar epithelium, cause shallow-layer to infect along the diffusion of mucosa face, and pathological changes is obvious with cervical canal.Diplococcus gonorrhoeae, in addition to invading cervical canal columnar epithelium, the most often attacks urethra transitional epithelium, paraurethral gland and greater vestibular gland.Staphylococcus, streptococcus are more easy to involve cervix uteri lymphatic vessel, invade cervix uteri interstitial deep.
Clinical manifestation
1. the cardinal symptom of acute cervicitis is leukorrhagia, in purulence or be mixed with blood.It is often accompanied by the urinary Tract Symptoms such as the soreness of waist, lumbago, hypogastric region bearing down, sexual anhedonia, frequent micturition, dysurea.Chlamydia trachomatis infection may occur in which the symptoms such as menorrhagia, intermenstrual bleeding, postcoital bleeding.Cervix uteri hyperemia, enlargement are shown in gynecologial examination, have purulent leukorrhea many from the outflow of cervix uteri mouth, amount, particularly gonococcal infection.Severe one is with rotten to the corn, downright bad, ulcer.And often exist with acute vaginitis, acute endometritis simultaneously.
2. gynecologial examination is shown in that trachelopanus, edema, mucosa turn up, and has purulent secretion to flow out from cervical canal, and cervix uteri is touched a tender spot, and matter is crisp, and that touches is the most hemorrhage.If infection due to Neisseria gonorrhoeae, because paraurethral gland, greater vestibular gland are got involved, it is seen that the hyperemia of urethral orifice, vaginal orifice mucosa, edema and volume purulent secretion.
The diagnosis of this disease relies primarily on the colposcopy of lab testing 1. acute cervicitis: cervix uteri is acute congestion shape, mucosa flushing, is covered with netted blood vessel or point-like, corkscrew vessels.Infect as merged body of gland, then cervical surface is dispersed in the multiple yellow vesicular pus points of distribution, and gland mouth is full of by pus.By low power lens under the background of cervix uteri acute congestion, it is covered with multiple yellow Semen setariae sample vesicular protuberance.Purulence embolus it is full of in cervical canal.2. secretions inspection: after wiping cervical surface secretions, take out in inserting cervical canal with little cotton swab, naked eyes are seen yellow or yellow green mucus purulent secretion on white cotton swab, secretions smear is made Gram's staining, if average each oil mirror visual field has more than 10 or each high power field has more than 30 neutrophilic granulocytes, the most diagnosable MPC under light microscopic.3. blood test is conventional: leukocyte increases.4. Pathogen culture and antibacterial sensitization test, elisa (ELISA) and detection of nucleic acids to medicine.
1. Drug therapy is administered orally anti-inflammatory treatment, available penicillin, Metronidazole Tablet.2. medicine is received in intravaginal, such as Metronidazole Tablet, vaginitis suppository, miconazole etc..3. mainly for pathogen, heavy dose of, single-dose is advocated for simple acute gonococcal cervicitis, conventional medicine has third generation cephalosporin (such as ceftriaxone, cefixime), quinolones (ciprofloxacin, ofloxacin) and spectinomycin.4. treatment chlamydia medicine has Tetracyclines (doxycycline), erythromycin series (azithromycin) and quinolones (ofloxacin, levofloxacin).5. treatment by Chinese herbs leukorrhagia can use traditional Chinese medical herbal treatment, and effectiveness comparison is preferable.Simultaneously it should be noted that diet and living habit.
Medical material involved in the present invention all seen from be recorded in " China book on Chinese herbal medicine ".
Summary of the invention
It is desirable to provide a kind of medicine under treatment belt, by selecting suitable medical material and proportioning thereof, reach safely and effectively to cure the purpose of leukorrhagia.
In order to achieve the above object, the present invention is by the following technical solutions:
A kind of medicine under treatment belt, it is characterized in that, it is to be prepared from by the raw medicinal material of following weight proportion: silver 10 parts of rattan of the back of the body, Herba Pachysandrae Terminalis 9 parts, Herba Hyperici Sampsonii 15 parts, chicken bone 9 parts, Herba Pleurospermi giraldii 9 parts, bracketplant 6 parts, Caulis Sargentodoxae 30 parts, Herba Patriniae 20 parts, Rhizoma Smilacis Glabrae 2O part, Spina Gleditsiae 10 parts, Myrrha 15 parts, Radix Puerariae 10 parts.
Illustrate the method have the benefit that below in conjunction with theories of Chinese materia medica
It has been recognised by the inventors that the basic pathogenesis of leukorrhagia affects mainly due to damp, appoint, to carry two arteries and veins to fail to keep an appointment caused.And damp divide inside and outside not, exogenous damp be by menstrual period, produce time, puerperal, and septic abortion, blood room just opening, and heresy that noxious dampness is foul is taken advantage of a weak point in opponent's defence and invaded, and directly hinders brain arteries and veins, so that dai channel is failed to keep an appointment forms leukorrhagia.Internal injury is then lost fortune by insufficiency of the spleen, and mistake of suffering from a deficiency of the kidney is solid, accumulates in turbid damp, and heat-transformation for a long time, and damp-heat gluing each other, the multiple abscess part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels forms leukorrhagia.Or because of depression of liver-QI, strongly fragrant long heat-transformation, warm is accumulate and is formed leukorrhagia in dai channel.So on Zhi Liao, answering treating both the principal and secondary aspects of a disease, with heat-clearing and toxic substances removing, eliminating dampness and arresting leucorrhea is main.
The present invention uses: silver back of the body rattan bitter in the mouth is cool in nature, and dissipating blood stasis stops blooding；Herba Pachysandrae Terminalis heat-clearing and toxic substances removing, regulating menstruation and activating blood, leukorrhagia stopping；Herba Hyperici Sampsonii heat-clearing and toxic substances removing, dredge the meridian passage, cooling blood for hemostasis；Chicken bone detoxicating, relieving inflammation, expelling wind and removing dampness；Herba Pleurospermi giraldii warming middle-JIAO is regulated the flow of vital energy, the spleen strengthening and damp drying, leukorrhagia stopping；The sub-nourishing the lung to arrest cough of bracketplant, dissipating blood stasis regulating menstruation；Caulis Sargentodoxae takes its heat-clearing and toxin-vanquishing, the merit of eliminating carbuncle eliminating stagnation, with its gesture of pause and transition in rhythm or melody, therefore is principal agent；Herba Patriniae, Rhizoma Smilacis Glabrae, Myrrha clearing heat, detoxicating, dispelling dampness, eliminating carbuncle evacuation of pus；Spina Gleditsiae expelling pus and toxin by strengthening QI, eliminating carbuncle；Radix Puerariae is pungent cool, returns taste two warp, takes its sending up the lucid YANG, inspires the gas of taste sun clearly to rise；All medicines share, and play the merit of heat clearing away, removing toxic substances, dampness removing altogether.
Below in conjunction with clinical laboratory data beneficial effects of the present invention is described:
1, physical data
Inventor collects 120 example leukorrhagia patients between 2012 06 month-2014 years 06 month altogether.It is randomly divided into: treatment group 60 example, matched group 60 example.25 ~ 45 years old age, average 36 ± 4.5 years old, the course of disease 5 ~ 10 days, average 7.56 ± 1.5 days.The data such as two groups of sexes, age, courses of disease there was no significant difference, and has comparability.
Diagnostic criteria
1. medical history: primary disease mostly occurs at puerperal or artificial abortion.
2. clinical manifestation: increase with vaginal secretions, white thickness or yellow green purulence, lumbago, lower abdomen discomfort is main clinical manifestation.If gonococcus infection person can be with heating, pruritus vulvae or urinary tract infection symptom.
3. gynecologial examination: trachelopanus, edema, there is contact bleeding local；Severe patient, its cervical surface epithelium strips off, downright bad, ulcer, and cervical mucosa is outwards routed up, and substantial amounts of mycopus is discharged in neck tube.
4. lab testing: visible a large amount of pus cells during cervical smear, can find antibacterial during row Gram’s staining；Cultivation of cervical secretions, can turn out pathogenic bacterium.
5. pathologic finding: uterine cervical squamous exuviation, inner membrance glandular secretion is hyperfunction, has a large amount of neutrophil infiltration around interstitial and body of gland；Severe person's neutrophilic granulocyte even reaches in gland epithelial cells in can invading people top layer.Tissue edema, vasodilation is congested, but acute inflammation stage does not the most make pathologic finding.
1. exclusion standard to drugs composition allergy, has serious adverse reaction；2. there are the important organ dysfunction persons such as severe cardiac, liver, kidney；3. gestation or women breast-feeding their children, allergic constitution person；4. during treating, the medicine person using other treatment leukorrhagia is merged, not by regulation pill taker.
2, Therapeutic Method
Treatment group is administered orally the capsule that the present invention prepares according to specific embodiment 3, three times a day.Treat 7.
Matched group Effect of Oral Metronidazole sheet, 200mg is each, 3 times/d；Erythromycin, 500mg is each, 4 times/d.Treat 7.
3, criterion of therapeutical effect and therapeutic outcome
3.1 criterion of therapeutical effect
1. recovery from illness: cervix uteri face smooth, rotten to the corn disappears, does not has that hemorrhage, color and luster is normal, external form approximation is normal, and it is normal that the amount of vaginal secretions, color, abnormal smells from the patient, matter are recovery, and all diseases disappear；
The most effective: the amount of vaginal secretions, color, abnormal smells from the patient, matter all alleviate；
The most invalid: all diseases of leukorrhagia are unchanged or increase the weight of.
3.2 treatment statistical results are shown in Table 1.
1 liang of table group comparitive study
Group n Recovery from illness Effectively Invalid Total effective rate (%) Obvious adverse reaction example
Treatment group 60 50 6 4 93.33% 0
Matched group 60 10 40 10 83.33% 0
Visible, medicine that the present invention prepares can be safely and effectively under treatment belt, and cure rate is high.
Detailed description of the invention
In order to be more fully understood that and implement the present invention, further illustrate the present invention below in conjunction with specific embodiment.
Embodiment 1
Weigh: silver 10 grams of rattan of the back of the body, Herba Pachysandrae Terminalis 9 grams, Herba Hyperici Sampsonii 15 grams, chicken bone 9 grams, Herba Pleurospermi giraldii 9 grams, bracketplant 6 grams, Caulis Sargentodoxae 30 grams, Herba Patriniae 20 grams, Rhizoma Smilacis Glabrae 2O gram, Spina Gleditsiae 10 grams, Myrrha 15 grams, Radix Puerariae 10 grams；Add 8 times amount water, decoct 1.5 hours, filter；Filtering residue adds 6 times amount water, decocts 1 hour, filters；Merging filtrate, is concentrated into 120 grams, must meet the decoct of one day consumption of adult normal.
Under treatment belt.Oral, the most once.
Embodiment 2
Weigh: silver 10 grams of rattan of the back of the body, Herba Pachysandrae Terminalis 9 grams, Herba Hyperici Sampsonii 15 grams, chicken bone 9 grams, Herba Pleurospermi giraldii 9 grams, bracketplant 6 grams, Caulis Sargentodoxae 30 grams, Herba Patriniae 20 grams, Rhizoma Smilacis Glabrae 2O gram, Spina Gleditsiae 10 grams, Myrrha 15 grams, Radix Puerariae 10 grams；Add 10 times amount water, decoct 2 hours, filter；Filtering residue adds 8 times amount water, decocts 1.5 hours, filters；Merging filtrate, concentrates, and is dried, and packaging must meet the powder of one day consumption of adult normal.
Under treatment belt.Oral, every bu is taken for twice sooner or later.
Embodiment 3
Weigh: silver 10 grams of rattan of the back of the body, Herba Pachysandrae Terminalis 9 grams, Herba Hyperici Sampsonii 15 grams, chicken bone 9 grams, Herba Pleurospermi giraldii 9 grams, bracketplant 6 grams, Caulis Sargentodoxae 30 grams, Herba Patriniae 20 grams, Rhizoma Smilacis Glabrae 2O gram, Spina Gleditsiae 10 grams, Myrrha 15 grams, Radix Puerariae 10 grams；Add 6 times amount water, decoct 3 times, decoct 1 hour every time, merge decoction liquor, concentrate, be dried, load capsule shells, the capsule of one day consumption of adult normal must be met.
Under treatment belt.Oral, every bu morning, noon and afternoon take for three times.

Claims (4)

1. the medicine under treatment belt, it is characterized in that, it is to be prepared from by the raw medicinal material of following weight proportion: silver 10 parts of rattan of the back of the body, Herba Pachysandrae Terminalis 9 parts, Herba Hyperici Sampsonii 15 parts, chicken bone 9 parts, Herba Pleurospermi giraldii 9 parts, bracketplant 6 parts, Caulis Sargentodoxae 30 parts, Herba Patriniae 20 parts, Rhizoma Smilacis Glabrae 2O part, Spina Gleditsiae 10 parts, Myrrha 15 parts, Radix Puerariae 10 parts.
2. the medicine under treatment belt as claimed in claim 1, it is characterized in that, its preparation method is: weigh: silver 10 parts of rattan of the back of the body, Herba Pachysandrae Terminalis 9 parts, Herba Hyperici Sampsonii 15 parts, chicken bone 9 parts, Herba Pleurospermi giraldii 9 parts, bracketplant 6 parts, Caulis Sargentodoxae 30 parts, Herba Patriniae 20 parts, Rhizoma Smilacis Glabrae 2O part, Spina Gleditsiae 10 parts, Myrrha 15 parts, Radix Puerariae 10 parts；Add 8 times amount water, decoct 1.5 hours, filter；Filtering residue adds 6 times amount water, decocts 1 hour, filters；Merging filtrate, is concentrated into 120 parts, obtains decoct；Above-mentioned part each means weight portion.
3. the medicine under treatment belt as claimed in claim 1, it is characterized in that, its preparation method is: weigh: Fructus Trichosanthis 9 parts, silver 10 parts of rattan of the back of the body, Herba Pachysandrae Terminalis 9 parts, Herba Hyperici Sampsonii 15 parts, chicken bone 9 parts, Herba Pleurospermi giraldii 9 parts, bracketplant 6 parts, Caulis Sargentodoxae 30 parts, Herba Patriniae 20 parts, Rhizoma Smilacis Glabrae 2O part, Spina Gleditsiae 10 parts, Myrrha 15 parts, Radix Puerariae 10 parts；Add 10 times amount water, decoct 2 hours, filter；Filtering residue adds 8 times amount water, decocts 1.5 hours, filters；Merging filtrate, concentrates, and is dried, and packaging obtains powder；Above-mentioned part each means weight portion.
4. the medicine under treatment belt as claimed in claim 1, it is characterized in that, its preparation method is: weigh: silver 10 parts of rattan of the back of the body, Herba Pachysandrae Terminalis 9 parts, Herba Hyperici Sampsonii 15 parts, chicken bone 9 parts, Herba Pleurospermi giraldii 9 parts, bracketplant 6 parts, Caulis Sargentodoxae 30 parts, Herba Patriniae 20 parts, Rhizoma Smilacis Glabrae 2O part, Spina Gleditsiae 10 parts, Myrrha 15 parts, Radix Puerariae 10 parts；Add 6 times amount water, decoct 3 times, decoct 1 hour every time, merge decoction liquor, concentrate, be dried, load capsule shells, obtain capsule；Above-mentioned part each means weight portion.
CN201610287707.4A 2016-05-04 2016-05-04 Drug for treating morbid leukorrhea Pending CN105833132A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610287707.4A CN105833132A (en) 2016-05-04 2016-05-04 Drug for treating morbid leukorrhea

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610287707.4A CN105833132A (en) 2016-05-04 2016-05-04 Drug for treating morbid leukorrhea

Publications (1)

Publication Number Publication Date
CN105833132A true CN105833132A (en) 2016-08-10

Family

ID=56590823

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610287707.4A Pending CN105833132A (en) 2016-05-04 2016-05-04 Drug for treating morbid leukorrhea

Country Status (1)

Country Link
CN (1) CN105833132A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104306498A (en) * 2014-11-05 2015-01-28 青岛恒波仪器有限公司 Traditional Chinese medicine composition for treating kidney deficiency cold-damp type leucorrhea of women and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104306498A (en) * 2014-11-05 2015-01-28 青岛恒波仪器有限公司 Traditional Chinese medicine composition for treating kidney deficiency cold-damp type leucorrhea of women and preparation method thereof

Similar Documents

Publication Publication Date Title
CN103721131A (en) Traditional Chinese medicinal suppository for treating female chronic pelvic inflammation and preparation method thereof
CN108992488A (en) A kind of Chinese medicine that treating rhinitis chronic and preparation method
CN104274788A (en) Traditional Chinese medicine composition for treating morbid leucorrhea due to liver-fire and damp-heat in women and preparation method of traditional Chinese medicine composition
CN103550709B (en) A kind of Chinese medicine for the treatment of chronic pelvic inflammatory disease
CN104906465A (en) Traditional Chinese medicine blood-stasis dispersing composition for treating woman chronic pelvic inflammation and preparation method thereof
CN104306637A (en) Traditional Chinese medicine composition for treating morbid leucorrhea of women with damp abundance due to spleen asthenia syndrome and preparation method of traditional Chinese medicine composition
CN101637552B (en) Chinese medicine compound for controlling chronic pelvic inflammation
CN102872300B (en) Traditional Chinese medicine for treating non-gonococcal urethritis
CN102600405B (en) Traditional Chinese medical composition for treating wet-hot type chronic pelvic inflammation and a preparation method thereof
CN104771578A (en) Traditional Chinese medicine for treating allergic rhinitis
CN104225218A (en) Traditional Chinese medicine preparation for chronic urinary infection treatment
CN102526620A (en) Traditional Chinese medicinal composition for treating gynecological inflammation and application of same
CN101366878A (en) Traditional Chinese medicine for female acyesis and aphoria and preparation method thereof
CN101884725B (en) Method for preparing Chinese medicinal lotion for treating initial acute mastitis
CN105833132A (en) Drug for treating morbid leukorrhea
CN105055831A (en) Traditional Chinese medicine for treating leukorrhagia of women and preparation method thereof
CN104367946A (en) Traditional Chinese medicine suppository for treating chronic endometritis and preparation method thereof
CN103494924B (en) Chinese medicine composition for treating damp-heat stagnation acne
CN103041194B (en) Traditional Chinese medicine composition for curing chronic eczema and preparation method thereof
CN105833220A (en) Traditional Chinese medicine composition for assistant treatment of gynecologic malignant tumors
CN104707124A (en) Traditional Chinese medicine preparation for treating chronic endometritis
CN105288436A (en) Medicament for treatment of chronic eczema
CN105148020A (en) Traditional Chinese medicine composition for treating qi-failing-to-control-blood type metrorrhagia and metrostaxis
CN104127814A (en) Traditional Chinese medicinal preparation for curing pelvic inflammation
CN104689253A (en) Traditional Chinese medicine composition for treating gallbladder removal syndromes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160810